Wall Street analyst estimates for KalVista Pharmaceuticals, Inc. (KALV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Valuation Ratios
| Price / Book | -503.31 |
| EV / EBITDA | -12.74 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $8.4M | $16.1M | $12.7M | 0 | 0 | 0 | 0 | 0 | $73.6M |
| Cost of Revenue | $12666 | $18237 | $35021 | $40.2M | $41.3M | 0 | 0 | $86.2M | 0 | $6.1M |
| Gross Profit | $1.5M | $8.4M | $16.1M | -$27.5M | -$41.3M | 0 | 0 | -$86.2M | 0 | $67.5M |
| Research & Development | $12.7M | $18.2M | $35.0M | $40.2M | $41.3M | $70.2M | $80.3M | $86.2M | $71.7M | $55.6M |
| Selling, General & Admin | $11.2M | $8.9M | $10.9M | $13.0M | $16.6M | $26.4M | $30.6M | $54.3M | $116.3M | $183.7M |
| Operating Expenses | $23.8M | $27.1M | $45.9M | $13.0M | $16.6M | $96.6M | $110.9M | $54.3M | $188.0M | $239.4M |
| Operating Income | -$22.3M | -$18.7M | -$29.8M | -$40.5M | -$57.9M | -$96.6M | -$110.9M | -$140.4M | -$188.0M | -$171.8M |
| EBITDA | -$22.3M | -$18.5M | -$29.4M | -$40.0M | -$57.4M | -$80.7M | -$94.4M | -$134.3M | -$173.3M | -$150.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.8M | $19.3M |
| Pre-tax Income | -$18.6M | -$15.8M | -$20.7M | -$29.0M | -$46.2M | -$82.3M | -$92.9M | -$135.1M | -$180.1M | -$171.4M |
| Income Tax | 0 | 0 | $124000 | $124000 | 0 | 0 | 0 | -$8.5M | $3.4M | -$7.1M |
| Net Income | -$18.6M | -$15.8M | -$20.8M | -$29.1M | -$46.2M | -$82.3M | -$92.9M | -$126.6M | -$183.4M | -$164.3M |
| EPS | $-1.92 | $-1.53 | $-1.38 | $-1.64 | $-2.33 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | $-3.23 |
| EPS (Diluted) | $-1.92 | $-1.53 | $-1.38 | $-1.64 | $-2.33 | $-3.36 | $-3.33 | $-3.44 | $-3.69 | $-3.23 |
| Shares Outstanding (Diluted) | $9.7M | $10.3M | $15.1M | $17.7M | $19.1M | $24.5M | $27.9M | $36.8M | $49.7M | $50.9M |
Price
| Price | $27.00 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explore sector: Healthcare · Biotechnology
More sections of KALV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks